585 results about "Acetaminophen" patented technology

Sustained release dosage forms for twice daily oral dosing to a human patient for providing relief from pain are provided. The sustained release dosage form comprises an immediate release component and a sustained release component, wherein the immediate release component and the sustained release component collectively contain a therapeutically effective amount of an opioid analgesic and a therapeutically effective amount of nonopioid analgesic. In a preferred embodiment, the nonopioid analgesic is acetaminophen and the opioid analgesic is hydrocodone and pharmaceutically acceptable salts thereof, and in preferred embodiments, the pharmaceutically acceptable salt is bitartrate. The dosage forms produce plasma profiles in a patient characterized by a Cmax for hydrocodone of between about 0.6 ng/mL/mg to about 1.4 ng/mL/mg and an AUC for hydrocodone of between about 9.1 ng*hr/mL/mg to about 19.9 ng*hr/mL/mg (per mg hydrocodone bitartrate administered) and a Cmax for acetaminophen of between about 2.8 ng/mL/mg and 7.9 ng/mL/mg and an AUC for acetaminophen of between about 28.6 ng*hr/mL/mg and about 59.1 ng*hr/mL/mg (per mg acetaminophen administered) after a single dose.

PCT No. PCT/FR97/01452 Sec. 371 Date Jun. 5, 1998 Sec. 102(e) Date Jun. 5, 1998 PCT Filed Aug. 5, 1997 PCT Pub. No. WO98/05314 PCT Pub. Date Feb. 12, 1998Novel stable paracetamol compositions for use in therapeutic chemistry and specifically galenic pharmacy are disclosed. The compositions contain a solution of paracetamol in an aqueous solvent combined with a buffer having a pH of 4 to 8, and a free radical capturing agent. A water-insoluble inert gas is carefully bubbled through the aqueous solvent to remove oxygen from the medium. Said compositions may also be combined with a centrally or peripherally acting analgesic agent, and are provided as injectable compositions for relieving pain.

The invention is directed to compositions comprising a nanoparticulate acetaminophen composition, or a salt or derivative thereof, having improved bioavailability. The nanoparticulate acetaminophen particles of the composition have an effective average particle size of less than about 2000 nm and are useful in the treatment of aches and pain, and in the reduction of fever and related conditions.

The present invention relates to monoeximic solid dosage forms for administering pharmaceutical agents, particularly Hydrocodone and acetaminophen, methods for preparing said dosage forms, and methods for providing therapeutic agents to patients in need of treatment.

The present invention relates generally to formulations comprising paracetamol. More particularly, the present invention provides a swallow formulation comprising paracetamol which facilitates the rapid delivery of paracetamol into the circulatory system following oral administration. The present invention further relates to methods for inducing efficient pain relief including an analgesic effect by the administration of the paracetamol formulation.

ABSTRACTA pharmaceutical composition comprises a combination of a selective or specific COX 2 inhibitor or a pharmaceutically acceptable salt or derivative thereof and an opiate or a pharmaceutically acceptable salt or derivative thereof, for example a combination of meloxicam and codeine, as active ingredients, and a pharmaceutically acceptable carrier. It may include a centrally-acting cyclo-oxygenase inhibitor such as paracetamol or its pharmaceutically acceptable salts or derivatives. The pharmaceutical compositions are used in methods of providing symptomatic relief or treatment of pain, in an algesic and/or hyperalgesic state, with or without fever, in particular that associated with inflammation such as that associated with trauma, osteoarthritis, rheumatoid arthritis, non-inflammatory myalgia or dysmenorrhoea

The present disclosure provides an extended release pharmaceutical composition comprising oxycodone and acetaminophen that provides a rapid onset of analgesia, and reduced levels of acetaminophen near the end of the dosing interval. Also provided are methods for reducing the risk of acetaminophen-induced hepatic damage in a subject being treated with an acetaminophen containing composition, as well as methods for treating pain in a subject in need thereof.

The invention discloses application of fructus forsythiae aglycone in preparing a medicament for preventing or treating liver injury or liver failure, and belongs to the medical field. The fructus forsythiae aglycone is a traditional Chinese medicine monomer obtained by extracting from the conventional fructus forsythiae, and is shown to have better treatment effect for the liver injury caused by acetaminopben, the livery injury caused by anti-tumor drug cis-platinum, acute or chronic livery injury caused by carbon tetrachloride, the livery injury caused by D-galactosamine and the liver failure caused by the D-galactosamine and lipopolysaccharide according to an animal test, has effect, which is better than that of fructus forsythiae and fructus forsythiae aglycone, in treating liver injury or liver failure. The fructus forsythiae aglycone is exact in curative effect and low in side effect for treating the liver injury and the liver failure, and has wide medical application prospect.

The invention particularly relates to a method for preparing a compound paracetamol and amantadine hydrochloride tablet, which belongs to the field of medicines. According to the method, submicron powder and ordinary fine powder which has been sieved with a 100-mesh sieve are mixed in proportion, a proper amount of accessories are added, and a prepared finished product is enabled to have better dissolvability, more than 90% on average. After six-month accelerated normal temperature stability experiments, the dissolvability of the finished product prepared by using the method is about 90%, and all the other indexes of the finished product accord with quality standard requirements.

The present invention provides hepatoprotectant acetaminophen mutual prodrugs, which have an acetaminophen moiety covalently linked to a second moiety that may act as a hepatoprotectant against acetaminophen hepatotoxicity. Additionally, acetaminophen mutual prodrugs may have improved water solubility which may provide better suitability for parenteral and other dosage forms relative to administration of acetaminophen. Also provided are methods of treating a disease or condition that is responsive to acetaminophen (such as fever, pain and ischemic injury) using hepatoprotectant acetaminophen mutual prodrugs, as well as kits and unit dosages.

An oral disintegrating tablet of paracetamol is prepared from paracetamol, water-soluble filler, disintegrant, lubricant, and wetting agent or adhesive.

The invention relates to the technical field of material preparation and electroanalytical chemistry, and concretely relates to a CoFe2O4NWs/RGO composite nano-material, and a paracetamol electrochemical sensor obtained through the composite nano-material. The composite nano-material is prepared through the following steps: S11, carrying out ultrasonic treatment on graphene oxide (GO) in water for 10-30 min, adding citric acid, and continuously carrying out ultrasonic treatment for 10-60 min to obtain a GO dispersion; S12, adding FeCl3.6H2O and CoCl2.6H2O to the GO dispersion, and carrying out ultrasonic treatment for 10-60 min; S13, adjusting the pH value of the above obtained dispersion to 9.5-10.5, adding hydrazine, stirring the dispersion and hydrazine for 30-120 min, and ageing the obtained mixture for 18-48 h; and S14, centrifuging the aged mixture, washing the centrifuged mixture, and drying the washed mixture to obtain the CoFe2O4NWs/RGO composite nano-material. An electrochemical electrode or the electrochemical sensor obtained through the composite nano-material has the advantages of good stability, low detection limit, high sensitivity and high selectivity in the paracetamol detection process.

The invention discloses a pediatric acetaminophen composition and relates to the technical field of pharmaceutic preparations. The composition comprises the following components by weight: 13-32% of acetaminophen, 32-40% of mannitol, 2-4% of gelatin, 0.2-1.0% of xanthan gum, 32-40% of hydroxypropyl-beta-cyclodextrin with a medium degree of substitution and 0.1-0.15% of sucralose. A prepared pediatric acetaminophen freeze-drying oral disintegrating tablet containing above components is simple in components, needs no water when being taken, do not need to be chewed, works rapidly, has few residues in intestinal tract, is full in absorption and less in side effect and good in taste; the disintegration time of the tablet is no more than 2 minutes in an oral cavity of a human body, so that pediatric acetaminophen freeze-drying oral disintegrating tablet is especially suitable for being taken by infant patients.